The COSMIC-021 study began in 2017 to analyze the effects of cabozantinib alone or in combination with atezolizumab in patients with advanced solid tumors. New results from the study’s expansion cohorts demonstrate the efficacy of the treatment combination in patients with advanced urothelial carcinoma (UC). The phase Ib study enrolled patients with inoperable locally advanced or metastatic UC into one of four cohorts: first-line cisplatin-eligible, first-line cisplatin-ineligible, previous platinum-containing chemotherapy, or previous immune checkpoint inhibitor (ICI)-treated. ...
Urothelial Carcinoma
Advertisement
Latest News
This newly developed assay can assess the genomic profile of ctDNA in patients with advanced UC.
Noah Hahn, MD, gives an overview of durvalumab with intravesical gemcitabine and docetaxel for BCG-unresponsive NMIBC.
Drs. Tawagi and Armstrong provide detail and discussion on the bladder cancer research from the 2025 ASCO GU meeting.
Dr. Sonpavde provides an update on the latest analysis from the phase 3 global study of EV in combination with pembro.
Dr. Sonpavde provides an overview of a phase I/II trial in progress on V940 (mRNA-4157) for resected high-risk MIUC.
Drs. Roupret and Houede dissect their research on the safety and efficacy of durvalumab with NAC for operable high-risk UTUC.
Advertisement
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Noah Hahn, MD, gives an overview of durvalumab with intravesical gemcitabine and docetaxel for BCG-unresponsive NMIBC.
Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.
Drs. Karine Tawagi and Samantha Armstrong expand on the prostate cancer discussions of note, including TALAPRO-2.
Drs. Tawagi and Armstrong provide detail and discussion on the bladder cancer research from the 2025 ASCO GU meeting.
Drs. Tawagi and Armstrong recap the hottest topics in kidney cancer research from the 2025 ASCO GU Cancers Symposium.
Dr. Sonpavde provides an update on the latest analysis from the phase 3 global study of EV in combination with pembro.
Advertisement
Advertisement
Latest News
Enzalutamide with [177Lu]Lu-PSMA-617 improved OS and HRQOL, along with PSA PFS.
Dr. Tan discusses the TALAPRO-2 study, PARP inhibitor synergy, HRR testing, and evolving treatment strategies in mCRPC.
A recent proof-of-concept study has further evaluated the efficacy of PSMA-guided MDT for oligometastatic RCC.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.